End of the year, chaos, following the ceremony to the two foreign companies have to change the boss

Nov. 10 hearing United States medical equipment maker Boston Scientific's global senior vice president, Wang Xin, president of Asia Pacific announced to employees a message, Wang Jian, vice president of science and technology in Greater China appointed Wang Jian, a straight line report to the Wang Xin, at the same time joined the Pocac Asia Pacific leadership team, effective from the 15th of this month.

At present, Wang Jian is the general manager of China and Hong Kong of CRBard. He has been rumored recently in BD Medical and its employees. Wang Jian will leave Bard to Poco as the general manager. Both parties confirmed this today news.

Prior to joining Bud, Wang Jian had a 11-year Johnson & Johnson career. He initially entered Johnson & Johnson as a Johnson & Johnson-based global clinical diagnostics medical business and returned to China in 2003 to serve as Johnson & Johnson's clinical diagnostic medical business OCD), was promoted to OCD Regional Manager, National Sales Manager, National Director until promoted to Johnson & Johnson Vice President, OCD General Manager, due to his excellent business skills.

In August 2014, Wang left the Johnson & Johnson OCD and entered the bank as vice president and general manager in mainland China and Hong Kong. In April this year, Becton Dickinson announced that with a cash and stock transaction of $ 24 billion Capital acquisition Bud.